Chiusura precedente | 0,4780 |
Aperto | 0,4700 |
Denaro | 0,4520 x N/D |
Lettera | 0,5050 x N/D |
Min-Max giorno | 0,4700 - 0,4740 |
Intervallo di 52 settimane | 0,2380 - 1,3400 |
Volume | |
Media Volume | 114 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | N/D |
Rapporto PE (ttm) | N/D |
EPS (ttm) | N/D |
Prossima data utili | 08 mag 2024 - 13 mag 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
GERMANTOWN, Maryland, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), continues to grow the Point of Care (POCare) network and infrastructure of its advanced therapeutic services and facilities business through its subsidiary Octomera, by partnering with CGT Global, a biomedical company dedicated to advancing medical science and patient therapies. The
Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support GERMANTOWN, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Orgenesis, a global biotech company working to unlock the full potential of cell and gene therapies
Reports Progress in Advancing the Rollout of the POCare Platform and POCare Therapeutic Pipeline Orgenesis to Host Conference Call Today at 8:00 AM ET GERMANTOWN, Md., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today provided a business update for the second quarter ended June 30, 2023. Vered Caplan, CEO of Orgenesis, said, “We are pleased to report